Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2003 Jul;47(7):2158-60.
doi: 10.1128/AAC.47.7.2158-2160.2003.

Effect of calcium carbonate on bioavailability of orally administered gemifloxacin

M W Pletz  1 , P Petzold, A Allen, O Burkhardt, H Lode
Affiliations
Clinical Trial

Effect of calcium carbonate on bioavailability of orally administered gemifloxacin

M W Pletz et al. Antimicrob Agents Chemother. 2003 Jul.

Abstract

We investigated the effect of calcium carbonate on the oral bioavailability of gemifloxacin. Gemifloxacin was administered alone, 2 h before, simultaneously, or 2 h after calcium carbonate in 16 volunteers. Data for 320 mg of gemifloxacin alone were as follows: maximum concentration of drug in serum (C(max)),13 microg/ml; half-life, 7.33 h; and area under the concentration-time curve from 0 h to infinity (AUC( infinity )), 6.79 microg. h/ml. Only simultaneous coadministration of calcium carbonate reduced C(max) (-17%) and AUC( infinity ) (-21%) significantly.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Arithmetic means of measured plasma concentration of gemifloxacin after administration of 320 mg of gemifloxacin alone (regimen A) and 2 h after 1,000 mg of calcium carbonate (regimen B), simultaneously with calcium carbonate (regimen C), and 2 h before calcium carbonate (regimen D) in 16 healthy volunteers. The direction of the error bars (standard deviation) is upwards for regimens A and D and downwards for regimens B and C.
See this image and copyright information in PMC

References

    1. Aminimanizani, A., P. Beringer, and R. Jelliffe. 2001. Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials. Clin. Pharmacokinet. 40:169-187. - PubMed
    1. Biedenbach, D. J., and R. N. Jones. 2002. Evaluation of in vitro susceptibility testing criteria for gemifloxacin when tested against Haemophilus influenzae strains with reduced susceptibility to ciprofloxacin and ofloxacin. Diagn. Microbiol. Infect. Dis. 43:323-326. - PubMed
    1. Boswell, F. J., J. M. Andrews, G. Jevons, and R. Wise. 2002. Comparison of the in vitro activities of several new fluoroquinolones against respiratory pathogens and their abilities to select fluoroquinolone resistance. J. Antimicrob. Chemother. 50:495-502. - PubMed
    1. Dunnett, C. W. 1995. A multiple comparisons procedure for comparing several treatments with a control. J. Am. Statist. Ass. 50:1096-1121.
    1. Flor, S., D. R. Guay, J. A. Opsahl, K. Tack, and G. R. Matzke. 1990. Effects of magnesium-aluminum hydroxide and calcium carbonate antacids on bioavailability of ofloxacin. Antimicrob. Agents Chemother. 34:2436-2438. - PMC - PubMed

Publication types

LinkOut - more resources